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Abstract
Background: Alzheimer's Disease (AD) affects a growing proportion of the population each year. Novel therapies on 
the horizon may slow the progress of AD symptoms and avoid cases altogether. Initiating treatment for the underlying 
pathology of AD would ideally be based on biomarker screening tools identifying pre-symptomatic individuals. Early-
stage modeling provides estimates of potential outcomes and informs policy development.
Methods: A time-to-event (TTE) simulation provided estimates of screening asymptomatic patients in the general 
population age ≥55 and treatment impact on the number of patients reaching AD. Patients were followed from AD 
screen until all-cause death. Baseline sensitivity and specificity were 0.87 and 0.78, with treatment on positive screen. 
Treatment slowed progression by 50%. Events were scheduled using literature-based age-dependent incidences of AD 
and death.
Results: The base case results indicated increased AD free years (AD-FYs) through delays in onset and a reduction of 20 
AD cases per 1000 screened individuals. Patients completely avoiding AD accounted for 61% of the incremental AD-FYs 
gained. Total years of treatment per 1000 screened patients was 2,611. The number-needed-to-screen was 51 and the 
number-needed-to-treat was 12 to avoid one case of AD. One-way sensitivity analysis indicated that duration of 
screening sensitivity and rescreen interval impact AD-FYs the most. A two-way sensitivity analysis found that for a test 
with an extended duration of sensitivity (15 years) the number of AD cases avoided was 6,000-7,000 cases for a test 
with higher sensitivity and specificity (0.90,0.90).
Conclusions: This study yielded valuable parameter range estimates at an early stage in the study of screening for AD. 
Analysis identified duration of screening sensitivity as a key variable that may be unavailable from clinical trials.
Background
Alzheimer's Disease (AD) is a well-known, degenerative
neurological disorder primarily affecting the elderly with
the potential for extremely poor quality of life and high
treatment costs. The increasing age of the general popu-
lation and the incidence of AD in the elderly means that
the burden of AD will continue to increase, with a pro-
jected prevalence of 8 million by the year 2050 [1,2]. Cur-
rent symptomatic treatments have a modest benefit on
cognitive symptoms of AD, but there is little evidence
that they modify the underlying cause of AD, thus limit-
ing their use as a preventive treatment in asymptomatic
patients.
In parallel to current drug development efforts aimed at
slowing the underlying progression of AD, various bio-
markers are currently being researched as diagnostic
tools. These biomarkers include a variety of imaging
techniques as well as assays that evaluate blood and cere-
brospinal fluid levels of markers that are believed to be
AD-specific [3-8]. These markers have demonstrated
modest predictive value for identifying patients at risk for
future conversion to AD when studied in patients who
already have mild cognitive defects [5-8]. Specifically, the
sensitivity of this test for conversion to AD is 0.87 and the
specificity is 0.78, representing the current state of
knowledge in AD screening.
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What is lacking in this parallel drug and biomarker
development is a framework for understanding how these
efforts might impact the onset of new cases or delay of
symptom onset. Researchers commonly use computer
simulation models to compare newly-developed treat-
ments or screening tools to existing standards of care [9-
14]. Modeling techniques are helpful to payer authorities
and policy makers who consider cost-effectiveness of
interventions when prioritizing research funding and
making coverage and reimbursement decisions. These
same modeling techniques can also be useful tools for cli-
nicians and researchers to establish the appropriate pop-
ulation to treat or narrow the efficacy range needed for a
drug in early stages of development to be commercially
viable. The application of modeling techniques to bio-
markers or imaging techniques may help address ques-
tions related to the value of testing. Questions include:1)
What risk level justifies screening?, 2) At what age is it
optimal to recommend that patients be screened?; 3)
When does screening become unnecessary given a series
of negative tests? In addition, it is critical to understand
the potential benefits of re-screening within the expected
age-range of disease onset.
Computer simulation techniques can be used to answer
the above questions by synthesizing the properties of the
screening test itself, the disease process, and potential
therapies for treating and preventing the disease. Quanti-
fying sensitivity and specificity and understanding their
predictive value is the primary objective in the early
stages of development of screening and treatment. Only
when sensitivity and specificity are linked to effectiveness
of a potential prevention therapy do the benefits to
patients and society from screening become apparent.
The field of AD research is at a critical juncture to benefit
from modeling: biomarker-based screening measures are
under development as are therapies that may modify the
underlying neuropathological disease process.
The objective of this study is to synthesize current
knowledge of the best-understood parameters and major
components of AD-screening: AD biomarkers, screening
strategies, prevention therapy, and progression of AD
upon diagnosis to quantify patient-specific outcomes
over a wide range of hypothetical scenarios. Collecting
the variables and quantifying potential outcomes at an
early stage provides a foundation for decision and policy
makers to approach the issues of screening for AD a pri-
ori in contrast to the historical approaches to other dis-
ease state screening.
Methods
This being one of the first simulation models evaluating
screening and treatment to delay or prevent clinical AD,
we provide explicit assumptions related to the base-case
population and their adherence and persistence with
treatment when a screen is positive. This allows an analy-
sis that focuses on the impact of the attributes of the
screening test on generalized AD outcomes. The assump-
tions characterizing the population to screen, rescreen-
ing, and persistence are examined through sensitivity
analysis; therapy adherence, emotional consequences of
screening, and adverse events of future treatments are
addressed in the discussion and limitations sections. Of
primary significance to this model is that the presence of
Alzheimer's disease neuropathology identified on screen-
ing would precede the onset of clinically significant
symptoms that would be diagnosed as dementia of the
Alzheimer's type. Therefore, this is a true screening
model for the presence of disease. For simplicity, we use
"AD" to refer to clinically-diagnosable dementia. A posi-
tive screen means that there is presence of AD neuropa-
thology but not necessarily clinical AD.
Decision Analytic Model
The screening model is programmed as a deployed soft-
ware application programmed in the CafeSim™ Java Sim-
ulation Development Environment. This tool is designed
for the development of decision models ranging from
decision trees, Markov models, Monte Carlo microsimu-
lations (fixed-time advance or time-to-event), to discrete
event simulation with queuing. Applying time-to-event
(TTE) to screening for AD was undertaken to provide
maximum flexibility for analysis on the attributes of
screening tests and treatments that postpone disease
onset.
The TTE distribution for an AD diagnosis has been
constructed using incidence data from the literature
[15,16] in conjunction with U.S. census data [17]. In the
same manner as a recent model of colon cancer screening
[18], the model assumes that AD onset can be repre-
sented by a non-homogeneous Poisson process [19,20].
Figure 1 shows two approximations (linear and exponen-
tial) of the cumulative hazard curve of females between
ages 75 and 85. For each simulated patient a random
number is drawn to determine if a hazard will occur and
if so in what piece (age) of the distribution. Smoother
approximations (e.g. using exponentials with piecewise
linear hazards) between age strata provide more realistic
estimates between adjacent strata. Figure 1 shows that at
earlier ages when the hazard is low, the discrepancy
between approximation methods is small. However, the
exponential approach captures the phenomena whereby
incidence changes substantially between adjacent pieces.
Figure 2 summarizes the general flow of the AD model
algorithm. Table 1 contains a complete list of literature
based default inputs.Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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Probabilities and Assumptions
Base-case model assumptions include: 1) The initially
simulated cohort of patients are all screened; 2) No
patient has AD at the time of screening; 3) All patients
initiate prevention therapy upon positive screen; 4)
Patients are 100% adherent to therapy (i.e., they take all
doses as prescribed); 5) Similar to tamoxifen to prevent
breast cancer recurrence, 22% discontinue treatment in
the first year, but the rest persist until AD onset) [21]; 6)
Patients are screened once at age 70; 7) The upper bound
of the model timeframe is 100 years of age, so patients
scheduled to get AD beyond age 100 do not get AD; 8)
The effectiveness of treatment is not dependent on how
far before disease onset it is given. The base-case model
simulates screening at age 70 in keeping with the inci-
dence of AD typically occurring later in life Screening as
early as age 50 and late as age 80 are tested in sensitivity
analysis.
The age-gender probabilities of AD diagnosis used to
construct the TTE-AD distribution are based upon an
analysis of patients from the Framingham study [15]. This
study was chosen because it was a longitudinal, popula-
tion-based, U.S. cohort that provided incidence and life-
time risk of AD adjusted for competing risk of death.
The effectiveness of AD prevention therapy is
expressed as the percentage of time by which it would
delay a patient's progression to AD. The default effective-
ness in the screening model is 50%. Therefore, if a patient
were scheduled to transition to mild AD in 2 years, then 2
years of prevention therapy would delay that transition by
1 year, extending the pre-mild AD period from 2 to 3
years. If the patient remained on therapy until onset the
maximum delay would be 2 years (t/2+t/4+t/8 ...--> t).
Sensitivity (default; 0.87) and specificity (default; 0.78)
are based upon a cerebrospinal fluid study measuring the
ratio of Aβ-42 to Aβ-40. The cohort was followed-up to
conversion from "mild cognitive impairment" (MCI) to
AD for a mean of 5.2 years (range 4.0-6.8 years) [7].
It is rare that a screening test that does not detect a
genetic marker has an infinite timeframe on sensitivity.
More likely is that the time before onset at which a bio-
marker is detectable is a function of when the pathologi-
cal process begins, implying that test sensitivity and
specificity should be a function of time until onset. Given
Figure 1 Incidence rates converted to event times using piecewise linear or exponential approximations. Example of a female screened be-
fore age 70, with incidence of AD at age 77 = 0.003, at age 82 = 0.074, at age 85 = 0.03. The y-axis is the cumulative probability of AD before the time 
shown.Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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Figure 2 AD screening model algorithm.Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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Table 1: Input Parameters for Base Case Model.
Screening
Sensitivity of Screening Test (0-10 yrs) 0.87 [7]
Sensitivity of Screening Test +10 yrs (= 1-specificity) 0.22 [7]
Simulated Age at First Screening 70
Interval Between Screens Once
Treatment
Effectiveness 50%
Adverse Event Rate (Years After Initiation)
Years After Initiation
0-1 1-5 5-10 10-15 15-20
AE Rate 10% 2% 2% 2% 2%
Discontinue Treatment Given AE No
AE Monitoring Interval (First Year) 0.5 yrs (= 2 in year 1)
General
% Cohort Male 46% [17]
Annual Discount Rate 3%
Treatment Persistence (Discontinuation)
In first 6 months In second 6 months
Alzheimer's Disease CI Model 1 [24] 0% 68%
Alzheimer's Disease CI Model 2 [26] 0% 47%
Breast Cancer Recurrence - Tamoxifen[21] 17% 5.1%
Hypertension ACE Inhibitors [23] 25% 4%
Incidence Rates
Age Gender Probability Patient Will Develop AD [15,16]Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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the lack of data on characteristics of this distribution our
model uses a base-case assumption that there is a time
limit on the sensitivity of a screening test to the biomark-
ers for AD and sensitivity analysis is conducted on this
assumption. Although evidence from current clinical lit-
erature indicates a shorter mean follow-up time [7,8,22],
clinical expert opinion suggests that currently recognized
markers are legitimate within a range of 10-15 years.
Consequently, we assume the base-case timeframe to be
10 years on sensitivity. If a patient is scheduled to get AD
beyond the 10-year limit we assume that the rate of true
positives is 1-specificity, i.e. using the false positive rate,
assuming that patients more than 10 years from AD onset
are indistinguishable from those who would never get
AD. As discussed earlier, we have populated the base case
model relying on simplifying assumptions to avoid erro-
neous conclusions about the screening test itself. In par-
ticular, we assume that once prevention treatment is
initiated all patients are 100% adherent until mild AD
diagnosis. This is an unlikely scenario in clinical practice
but the adverse event profiles, onset of therapeutic effect,
and cost of novel AD therapies such as gamma secretase
inhibitors and antibodies are still unknown. However, we
address adherence to therapy in the discussion and limi-
tations sections. Therefore, we chose to evaluate the
impact of persistence in sensitivity analysis by modeling
persistence in a pattern similar to previous AD studies as
well as prevention or treatment of other diseases found in
the literature [21,23,24]. Specifically, we have modeled
persistence in a manner similar to that for the prevention
of breast cancer relapse in remitted patients taking
tamoxifen [21]. We have also used persistence rates for
studies in AD patients treated with cholinesterase inhibi-
tors. These likely represent a lower bound for persistence
due to their limited effectiveness and adverse event pro-
file [25,26]. Finally, we have included analysis using data
from literature on persistence with hypertension and sta-
tin therapies as an example of prevention therapy for
insidious disease [23,27] as well as an examination of
unending persistence.
Outcomes of the Analysis
This model provides the following relevant outcomes:
1. AD-free years (AD-FYs)
2. Number of patients to AD
3. Mean years of AD prevention treatment
4. Number of patients recommended for treatment on
first screen
5. Number Needed to Screen (NNS) to avoid one case
of AD
6. Number needed to treat (NNT) to avoid one case of
AD
7. AD-FYs gained per person year of prevention treat-
ment
8. AD cases avoided per person year of treatment
One-way sensitivity analysis was performed by varying
parameters within clinically relevant ranges. The results
of these analyses are displayed as tornado diagrams. Each
bar in the tornado diagrams represent the range of output
values achieved varying one of the inputs listed below:
1. Treatment effectiveness
2. Patient age at initial screen
3. Re-screening interval
4. Years of screening sensitivity
5. Persistence patterns
Male Female
50-54 (Value at age 52 in distribution) 0 0
55-59 (57) 0 0
60-64 (62) 0 0
65-69 (67) 0.0007 0.0002
70-74 (72) 0.0014 0.0004
75-79 (77) 0.0025 0.003
80-84 (82) 0.0065 0.0074
85+ (Constant for ages 85-100) 0.016 0.03
Table 1: Input Parameters for Base Case Model. (Continued)Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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The input with the greatest impact on the output in
question is at the top of each tornado diagram and those
with the least are at the bottom. Additional two-way sen-
sitivity analysis on screening sensitivity and specificity
was performed to determine their combined effect on the
number of AD cases avoided in the general population
(Figure 3).
Results
Table 2 shows the base case results where the model pre-
dicted an increase in AD-FYs through delays in onset and
a reduction of 20 AD cases per 1000 individuals screened.
Auxiliary calculations showed that approximately 61% of
the incremental AD free years gained were among the
patients that avoided AD, the rest were gained by patients
who had their AD onset delayed. The total number of
years of treatment per 1000 screened patients was 2,611
reflecting the conservative assumption that screening is
performed once at age 70 as well as the application of
conservative persistence assumptions. Additionally, the
NNS was 51 and NNT 12 to avoid one case of AD when
screening 100,000 patients given default incidence.
Figure 3 displays a two-way sensitivity analysis of test
sensitivity and specificity on AD cases avoided, when
screening at age 70 and the duration of sensitivity is 15
years. The duration of sensitivity represents the period
during which a marker for AD could be detected. There-
fore, outside the timeframe of test sensitivity, 1-specific-
ity is used for the sensitivity. Results indicate that a
perfect test followed by perfect adherence to a 50% effec-
tive treatment could prevent AD in 7-8% of people
screened (7,000-8,000 cases avoided per 100,000 persons
screened). Nearly a 20% reduction in specificity or a 40%
reduction in sensitivity is needed to reduce AD cases
avoided by an absolute 1% (1000 per 100,000 persons
screened). The reference case with a highly specific and
sensitive test (0.90, 0.90) indicates screening has the
potential to avoid AD in 6-7% of a screened population.
For moderate rates of sensitivity and specificity (0.80,
0.80) the proportion avoiding AD is slightly below 6%.
Other two-way analyses (not shown) indicated that for a
screening test with shorter duration of sensitivity, test
sensitivity and specificity were even less important.
Results for one-way sensitivity analysis summarized in
Figures 4 and 5 show the range of variation due to uncer-
tainty in five additional inputs. In general, these results
indicate that years of screening sensitivity and the
rescreen interval are the two main drivers of AD-FYs
(Figure 4) and AD cases avoided (Figure 5). The upper
range of sensitivity duration for one-way analysis was 25
years and yielded 424 AD-FYs and 63 AD cases avoided.
These may be considered extreme bounds as it is likely
that screening sensitivity to detect a non-genetic marker
would be no more than 10-15 years prior to onset. As
expected, the frequency of rescreening improves AD-FY
and AD cases avoided.
Additional one-way sensitivity analyses (Figures 6 and
7) showed that therapy persistence yielded the widest
range of values for NNT and NNS outcomes, reflecting
the underlying effect of treatment effectiveness. Given a
discrete effectiveness (50% in the base case) the longer
patients remain on therapy the greater the benefit and the
fewer NNT and NNS required for a success. In the case of
AD, this means that patients avoid the debilitating decline
of AD and die from other causes.
Discussion and Conclusions
To our knowledge, few studies in the literature have
attempted to model screening for AD. Previously pub-
lished studies have used a Markov modeling framework
to evaluate the cost-effectiveness of treatment of AD (e.g.
donepezil) [28-31]. First, these studies are limited in that
they are treatment models for AD and do not contain
screening components. Second, these studies rely on
Markov cohort models which cannot represent the
dynamic nature of cognitive impairment in patients of
different ages and gender. Third, the inherent fixed-time
advance mechanism may artificially limit the flexibility in
evaluating screening options and may miss interim
opportunities to intervene on behalf of patients. Finally,
Markov models are cumbersome when expansion of
health states, attributes, and assumptions are necessary.
This model provides a framework within which key
screening parameters can be tested, adjusted, and easily
expanded as the role of AD screening takes shape.
Our TTE simulation establishes a foundation for
numerous sensitivity analyses by simulating the many
variables associated with AD and its dynamic nature.
Additionally, there are potential implications of this
model in terms of policy debate and establishing screen-
ing guidelines should future developments warrant them.
As has been the case with mammograms [32], pap smears
[33] and colorectal cancer screening [34,35], modeling
can be a valuable tool in framing questions related to
screening and defining a range of parameters within
which society can benefit. Recently published results on
screening for prostate cancer highlight a potential benefit
from early stage modeling when determining the net ben-
efits to patients and society [36]. Early, thoughtful, struc-
tured analyses akin to those presented in this work can
potentially play a role in allaying societal stigmas associ-
ated with positive AD screens by assuring all stakeholders
that intervention is beneficial.
In keeping with the study objective we have determined
through hypothetical, credible scenarios that the effec-
tiveness of screening for AD is most influenced by:
Screening test sensitivity, duration of test sensitivity, effi-
cacy of AD prevention therapy, persistence on treatment,Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
http://www.biomedcentral.com/1472-6947/10/24
Page 8 of 12
and initial screening age. In particular, these analyses
have allowed us to draw focus to the age to begin screen-
ing and possibly, the age at which to stop. For example,
AD incidence is relatively low before age 80, but after 85
there may be little to be gained from delaying AD, due to
death from other causes when only considering death and
quality of the end of life. With a starting age of 70,
increasing the number of years during which a test is sen-
sitive rapidly improves the effectiveness of screening. If
such an increase in time-frame of sensitivity is not possi-
ble, the model allows the user to define a range in which
re-screening adds value.
We have chosen to limit the inputs, states, and assump-
tions in this version of the model to provide an unclut-
tered foundation for the fundamental variables involved
and their basic interactions. Although this serves the pur-
pose of creating a scalable instrument, it stands as a limi-
tation in the short term. First, the narrow age-gender
cohort we have chosen does not consider subpopulations.
It is likely that if screening for AD were to become viable,
it would be most effective and cost-effective in high-risk
cohorts. This model does not currently attempt to
address risk in subpopulations through attributes known
to be indicators of a higher probability of AD later in life.
Subpopulation analysis is likely to be the first expansion
of the model in the future when questions on cost-effec-
tiveness come to the fore.
Second, the model is limited by the lack of data on the
precursor health states of mild AD. Indeed the diagnostic
criteria and their corresponding accuracy are ambiguous
within the current literature [37-39]. A consistent clinical
approach to evaluating precursor states may encourage
ongoing engagement from stakeholders and prevent
more cases later in life. A lack of a definitive precursor
state may lead to lower adherence and persistence to
therapy as if it were not needed.
Third, the large amount of uncertainty in the AD
screening test is the primary motivation for this study but
it remains a limitation as well. We have attempted to
adopt sensitivity and specificity assumptions that pass
face validity according to the state of knowledge in AD
research and the expectations of clinicians in the AD
field. The assumptions in the model are based upon stud-
ies reporting conversion from MCI-like states to AD and
may represent an overestimate of future screening test
attributes. However, if a screening test exceeds expecta-
tions, is low-cost, and is relatively non-invasive, the
screening sensitivity and specificity may be underesti-
mated. Ultimately acceptable thresholds for screening
characteristics incorporated into future clinical practice
Figure 3 Two-way sensitivity analysis of screening sensitivity and specificity on AD cases avoided. AD cases avoided/100,000 screened, Age 
70 at first Screen, 46% male, 15-year sensitivity.Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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will surely address fundamental questions: Is society will-
ing to accept a screening test less sensitive and specific
compared to screening methods currently considered
acceptable in the general public (due to the increased
incidence of AD with an aging population)? Or, will the
AD screening test be held to a higher standard due to
patient anxiety and potential stigmatization on a positive
screen for AD?
Fourth, there is no data to directly support persistence
assumptions as the hypothetical therapies alluded to here
are still in development. However, we have made an
attempt to provide estimates using literature-based val-
ues for other well-known conditions spanning the spec-
trum from hypertension to breast cancer. These proxy
states are the current best estimates until the efficacy and
side effect profiles of novel AD therapies come to light.
Additionally, there are no data yet available to appropri-
ately inform how the emotional consequences of screen-
ing for AD should be parameterized. The trade-off
between the anxiety of screening and the long-term con-
Table 2: Base Case Results (Per 1000 Screened).
No Screening Screening Incremental
Alzheimer's Disease Free Years 13,677 13,834 + 157
Alzheimer's Disease Cases 113 93 - (20)
Total Years of Treatment 0 2,611 + 2,611
Number Recommended for Tx 0 236 + 236
NNS to Prevent 1 AD Case 51
NNT to Prevent 1 AD Case 12
AD-FY Gain/Person Yr of Treatment 0.0602
AD Case Avoided/Person Yr of Treatment 0.0076
Figure 4 One-way sensitivity on AD-Free Years (ADFYs).Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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sequences of disease are difficult to quantify, except over
very short timeframes when evaluating quality-of life
adjustments. Moreover, recent developments in age
thresholds and policies when screening for breast cancer
indicate that the effect of anxiety in screening paradigms
can shift. Avoiding undue anxiety when screening women
at age 40 has been cited as a benefit to extending the ini-
tial screen age to 50, but some evidence suggests that
patients understand the concept of false positives and are
willing to tolerate periods of anxiety to prevent cases of
death due to breast cancer [40,41]. Adherence to therapy
and adverse event profiles, inextricably linked to the
stigma of disease, represent possibly the most complex
interaction of factors that might impact future AD
screening efforts. This study does not attempt to address
these phenomena but the simulation contains functional-
ity to accept them at will should evidence arise to inform
parameter estimates.
Finally, the duration of the sensitivity of the test
remains a limitation. Ideally, the marker being screened
for would have a long duration of sensitivity which would
be encouraging for future use of the test. This is rarely the
case (except in the case of a genetic marker) and the exist-
ing base model uses a 10-year duration of sensitivity that
possesses face validity in the eye of clinicians experienced
in the diagnosis and treatment of AD. Our assumption of
10 years of sensitivity has necessarily placed focus on age
70 as the most likely age of initial screening. Screening at
younger ages increases the influence of the specificity of
the screening test and screening at ages much later limits
Figure 5 One-way sensitivity on mild AD cases avoided.
Figure 6 One-way sensitivity on NNT.Furiak et al. BMC Medical Informatics and Decision Making 2010, 10:24
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potential benefits and may be impractical due to the char-
acteristics of therapy, specifically, adverse events. We
have intentionally avoided cost estimates in this study
given that the screening and therapy are hypothetical (i.e.,
no market value available). However, the age at initial
screen may cover a wide range due to the high annual
cost of AD cases to payers, caregivers, and society in gen-
eral. Thus, screening at age 80 and delaying the onset of
AD beyond the time within which other causes of death
prevail might improve overall quality at the end of the
patient's live (versus severe cases of AD, for example).
Despite these limitations, the model provides a novel,
useful heuristic for researchers and clinicians as they
design studies to aid further development in AD and
other neurodegenerative diseases, such as Parkinson's
disease. The TTE approach is well-suited to assessment
of screening and intervention of neurodegenerative dis-
eases because of the need to account for the high degree
of variability in disease progression and potential differ-
entiating risk factors. This study has met a critical object
in that it has provided a range of estimates for outcomes
that will be helpful in the early debate of the issues relat-
ing to screening and therapy for AD.
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